Trial Profile
A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Bevacizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 22 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.